Bottom line
XLV vs PPH: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and PPH (VanEck Pharmaceutical ETF) share a meaningful slice of their top holdings — about 43% by weight.
But XLV is far broader, holding 65 positions to 26 for PPH, so beyond the top names it adds exposure PPH doesn't have.
XLV is cheaper at 0.08% vs 0.36% — a difference of $28 a year per $10,000 invested.
Over five years, PPH returned +11.3% a year vs +8.1% for XLV.
Updated Nov 19, 2026
XLV vs PPH side by side
| XLV | PPH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | VanEck |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.36% |
| Annual cost per $10k | $8 | $36 |
| 10-yr cost on $10k (prospectus) | $103 | $456 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +21.9% |
| 5-yr return (annualized) | +8.1% | +11.3% |
| 10-yr return (annualized) | +9.8% | +6.7% |
| Best quarter | +14.5% | +16.5% |
| Worst quarter | −12.7% | −15.0% |
| Net assets (fund) | $40.6B | $879.5M |
| Number of holdings | 65 | 26 |
| Portfolio turnover | 2% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | PPH | Difference |
|---|---|---|---|
| 2025 | +14.5% | +21.9% | −7.4% |
| 2024 | +2.5% | +8.1% | −5.6% |
| 2023 | +2.0% | +6.9% | −4.9% |
| 2022 | −2.1% | +2.6% | −4.7% |
| 2021 | +25.9% | +18.3% | +7.6% |
| 2020 | +13.3% | +5.2% | +8.1% |
| 2019 | +20.7% | +19.1% | +1.5% |
| 2018 | +6.3% | −5.7% | +12.0% |
| 2017 | +21.7% | +15.4% | +6.3% |
| 2016 | −2.8% | −17.8% | +14.9% |
Source: Fund prospectus bar charts
Holdings overlap
8 of XLV's top 25 holdings also appear in PPH's top 25.
| Holding | XLV | PPH |
|---|---|---|
| Eli Lilly & Co | 16.51% | 20.23% |
| Johnson & Johnson | 10.64% | 4.35% |
| AbbVie Inc | 7.74% | 4.57% |
| Merck & Co Inc | 5.52% | 9.85% |
| Pfizer Inc | 2.39% | 4.51% |
| Bristol-Myers Squibb Co | 2.05% | 4.47% |
| McKesson Corp | 1.58% | 4.12% |
| Cencora Inc | 0.96% | 3.36% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
PPH top 10
- Eli Lilly & Co — 20.23%
- Novartis AG — 10.63%
- Merck & Co Inc — 9.85%
- Novo Nordisk A/S — 5.37%
- AbbVie Inc — 4.57%
- Pfizer Inc — 4.51%
- Bristol-Myers Squibb Co — 4.47%
- Gsk Plc — 4.42%
- Johnson & Johnson — 4.35%
- AstraZeneca PLC — 4.33%
FAQ
What is the difference between XLV and PPH?
Which is cheaper, XLV or PPH?
Should I own both XLV and PPH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.